IL104916A0 - Use of interleukin-10 to suppress graft-vs.-host disease - Google Patents

Use of interleukin-10 to suppress graft-vs.-host disease

Info

Publication number
IL104916A0
IL104916A0 IL104916A IL10491693A IL104916A0 IL 104916 A0 IL104916 A0 IL 104916A0 IL 104916 A IL104916 A IL 104916A IL 10491693 A IL10491693 A IL 10491693A IL 104916 A0 IL104916 A0 IL 104916A0
Authority
IL
Israel
Prior art keywords
interleukin
host disease
suppress graft
graft
suppress
Prior art date
Application number
IL104916A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of IL104916A0 publication Critical patent/IL104916A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL104916A 1992-03-04 1993-03-02 Use of interleukin-10 to suppress graft-vs.-host disease IL104916A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84620892A 1992-03-04 1992-03-04

Publications (1)

Publication Number Publication Date
IL104916A0 true IL104916A0 (en) 1993-07-08

Family

ID=25297256

Family Applications (1)

Application Number Title Priority Date Filing Date
IL104916A IL104916A0 (en) 1992-03-04 1993-03-02 Use of interleukin-10 to suppress graft-vs.-host disease

Country Status (11)

Country Link
EP (1) EP0629130A1 (ko)
JP (1) JPH07504437A (ko)
KR (1) KR950700079A (ko)
CN (1) CN1079166A (ko)
AU (1) AU679908B2 (ko)
CA (1) CA2131524A1 (ko)
IL (1) IL104916A0 (ko)
MX (1) MX9301192A (ko)
NZ (1) NZ249754A (ko)
WO (1) WO1993017698A1 (ko)
ZA (1) ZA931489B (ko)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08510719A (ja) * 1993-02-01 1996-11-12 ユニヴェルシテ リブル ドゥ ブリュッセル アンスティテュション ダンセニュマン ユニヴェルシテル 有効量のインターロイキン−１０、その類似体および／または作動薬を含有する医薬組成物の使用
US5573764A (en) * 1994-01-21 1996-11-12 Genetics Institute, Inc. Use of interleukin-12 to prevent graft versus host disease
AP690A (en) * 1994-07-05 1998-10-16 Steeno Res Group A/S Immunomodulators based on a polypeptide other than human interleukin 10.
CA2216090A1 (en) * 1995-03-23 1996-09-26 Governors Of Dalhousie College And University A process of prolonging organ allograft survival
AU712606B2 (en) * 1995-08-09 1999-11-11 Schering Corporation Combined use of interleukin-10 and cyclosporin for immunosuppression therapy
US6022536A (en) * 1995-08-09 2000-02-08 Schering Corporation Combined use of interleukin 10 and cyclosporin for immunosuppression therapy
WO1997026278A1 (en) 1996-01-18 1997-07-24 Steeno Research Group A/S Synthetic il-10 analogues
US6090413A (en) * 1996-03-25 2000-07-18 Lee; Timothy D. Process of prolonging organ allograft survival
WO1998010792A1 (en) * 1996-09-11 1998-03-19 Prendergast Patrick T Immune direction therapy
WO1998020033A2 (en) * 1996-11-06 1998-05-14 Schering Corporation RENATURATION AND PURIFICATION OF VIRAL INTERLEUKIN-10 (vIL-10)
US6358506B1 (en) 1997-11-05 2002-03-19 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
WO1999030730A1 (en) * 1997-12-15 1999-06-24 Universite Laval Methods and compositions for improving the success of cell transplantation in a host
US6803036B1 (en) 1998-03-03 2004-10-12 University Of Southern California Use of cytokines, cells and mitogens to inhibit graft versus host disease
US6447765B1 (en) 1998-03-03 2002-09-10 University Of Southern California Use of cytokines and mitogens to inhibit graft versus host disease
US6759035B2 (en) 2000-04-11 2004-07-06 University Of Southen California Method to prevent graft rejection using TGF-beta to induce T suppressor cells
CN105106214A (zh) * 2015-08-05 2015-12-02 范国煌 抑制移植物抗宿主病的新型Lck的小分子抑制剂
SG10201606949QA (en) 2016-08-19 2018-03-28 Singapore Health Serv Pte Ltd Immunosuppressive composition for use in treating immunological disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same

Also Published As

Publication number Publication date
KR950700079A (ko) 1995-01-16
NZ249754A (en) 1997-06-24
EP0629130A1 (en) 1994-12-21
ZA931489B (en) 1993-10-28
MX9301192A (es) 1994-08-31
CN1079166A (zh) 1993-12-08
WO1993017698A1 (en) 1993-09-16
AU3732893A (en) 1993-10-05
AU679908B2 (en) 1997-07-17
CA2131524A1 (en) 1993-09-16
JPH07504437A (ja) 1995-05-18

Similar Documents

Publication Publication Date Title
IL104916A0 (en) Use of interleukin-10 to suppress graft-vs.-host disease
HU9303604D0 (en) Use of purified surface modifiers to prevent particle aggregation during sterilization
AU5006993A (en) Novel attachment of polyalkylene oxides to bio-effecting substances
HUT73102A (en) Purification of human interleukin-10
IL105966A0 (en) Preparation of clavulanic acid
AU2921192A (en) Purification of tri-alkyl compounds of group 3a metals
CS55092A3 (en) Improved use of organic compounds
IL105321A0 (en) Preparation of cinnamic acid derivatives
IL108047A0 (en) Therapeutic for gram-positive diseases of aquatic species
ZA935647B (en) Treatment of sickle cell disease
EP0522157A4 (en) Novel use of alkanamidocarboxybetaine
EP0559894A4 (en) Novel use of alkanamidoammonium compound
GB2202845B (en) Intermediates and processes for the preparation of antihypercholesterolemic tetrazole compounds
GR870501B (en) Use of malonic acid derivative compounds for increasing cropyield
AU8900891A (en) Direct oxidation of propylene to propylene oxide
GB2186580B (en) Purification of recombinant human interleukin-la
GB2244706B (en) Preparation of antihypercholesterolemic tetrazole intermediates
ZA913275B (en) Catalytic equilibration to improve the relative yield of selected halocarbons
DE3364700D1 (en) Preparation of penicillin and cephalosporin compounds and novel intermediates useful therein
IL98520A0 (en) Purification of diaminodiphenyl compounds
GB2282810B (en) Preparation or purification of clavulanic acid
GB8712144D0 (en) Purification of phenyl ethyl alcohol
GB9216105D0 (en) Improvements relating to wheelchairs
GB8700210D0 (en) Body to tube attachment
GB9226769D0 (en) Improvements relating to filters